Singapore Exchange Limited 1Q FY2009 Financial Results
|
|
- Maximillian Crawford
- 5 years ago
- Views:
Transcription
1 Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1
2 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008 Strong growth in net derivatives clearing revenue Expenses fell with lower variable bonus provision Operating leverage improved to 157% 2
3 Q1 FY09 vs Q1 FY08 Drop from record quarter In (S$M) 1Q FY09 1Q FY08 Y o Y Change Securities Market Revenue % Net Derivatives Clearing Revenue % Stable Revenue % Operating Revenue % Operating Expenses % Operating Profit % Other gains/ (losses) (1.6) (1.0) NM Net Profit after tax % ROE in % (quarterly figure) 9.1* % * The 1Q FY2009 ROE figure is relatively lower compared to 1Q FY2008 because of the later timing of this year s Annual General Meeting of which the final dividend for FY2008 was approved. If the proposed dividend had been removed from the equity base as per 1Q FY2008, the ROE would be 13.6%. 3
4 Q1 FY09 vs Q4 FY08 Flat operating profit In (S$M) 1Q FY09 4Q FY08 Q o Q Change Securities Market Revenue % Net Derivatives Clearing Revenue % Stable Revenue % Operating Revenue % Operating Expenses % Operating Profit % Other gains/ (losses) (1.6) 4.3 NM Net Profit after tax % ROE in % (quarterly figure) 9.1* % * The 1Q FY2009 ROE figure is relatively lower compared to 1Q FY2008 because of the later timing of this year s Annual General Meeting of which the final dividend for FY2008 was approved. If the proposed dividend had been removed from the equity base as per 1Q FY2008, the ROE would be 13.6%. 4
5 Financial Highlights (in S$M) ** 130 *** * Q FY06 2Q FY06 3Q FY06 4Q FY06 1Q FY07 2Q FY07 3Q FY07 4Q FY07 1Q FY08 2Q FY08 3Q FY08 4Q FY08 1Q FY09 Operating Revenue Net Profit After Tax Operating Expenses * Excludes the S$45.0 million write back of allowance for impairment on SGX Centre ** Excludes the S$65.5 million gain on disposal of SGX Centre *** Excludes the S$34.0 million distribution from SGX DT Compensation Fund 5
6 Operating Leverage (in S$M) Operating Leverage* 1Q FY09 157% 4Q FY08 120% Q FY08 135% FY08 132% Stable revenue Net derivatives clearing revenue * Operating FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY Securities market revenue 172 Operating expenses FY07 119% FY06 108% Leverage = Coverage of total operating expenses by derivatives revenue and stable revenue 6
7 Revenue (S$M) Derivatives Revenue Other products & services Structured warrants MSCI Singapore CNX Nifty MSCI Taiwan Nikkei FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY Q FY09 on 4Q FY08 11% 21% increase in futures trading volume 7
8 Stable Revenue (S$M) Others Membership fees Terminal & Connection fees Price information fees Listing fees Account Main. & Corporate Action fees FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY09 1Q FY09 on 4Q FY08 7% 20% decrease in account maintenance & corporate action fees 8
9 Operating Expenses Highlights S$M 1Q FY08 4Q FY08 1Q FY Q FY09 on 4Q FY08 22% 61% decrease in variable bonus 0.0 St af f Cost s (excl VB) Variable Bonus Syst em Maint. & Depreciat ion Cost f or processing & Ot hers * Rent al royalt ies * includes share based payment expense, rental and maintenance of premises, professional charges, marketing & travelling, communication charges, fees to MAS for transfer of participant supervision function, net foreign exchange loss/ gain, net loss on disposal of property, plant and equipment and software, and other operating expenses. 9
10 Performance at a Glance FY2006 FY2007* FY2008** 1Q FY2009 Return on Equity 32.0% 37.5% 49.7% 36.4%*** Cost to Income 45.1% 36.6% 31.2% 33.7% Net Profit Margin 44.6% 52.5% 56.8% 53.9% Regular dividend (Net) Base (cents per share) Variable (cents per share) * FY2007 figures exclude the writeback of allowance for impairment on SGX Centre and gain on disposal of SGX Centre ** FY2008 figures exclude distribution from SGX DT Compensation Fund *** Annualised figure. The 1Q FY2009 ROE figure is relatively lower compared to 1Q FY2008 because of the later timing of this year s Annual General Meeting of which the final dividend for FY2008 was approved. If the proposed dividend had been removed from the equity base as per 1Q FY2008, the ROE would be 13.6%. The annualised ROE would be 54.4%. 10
11 Building An Enduring Marketplace Asian Gateway Domestic Growth Asian Listing Platform Structured Products Risk Management Centre Singapore Equity Derivatives Partnerships & Alliances Retail Penetration Post Trade Processing Hub Market Oriented Regulation Operational & Technology Efficiency Customer focused Organisation Delivery Excellence 11
12 Connections of the Asian Gateway Asian Gateway Capital Raising Platforms Risk Management Centre Xinhua A50 Futures MSCI Taiwan Futures CNX Nifty Index Futures Nikkei Index Futures Euroyen Futures Structured Warrants MSCI India ETF S&P Nifty ETF Japan, Korea & ASEAN ETF Structured Warrants 217 listings: 150 China 49 Hong Kong 18 Taiwan Greater China 5 listings & 9 Global Depository Receipts (GDRs) India 64 listings: 55 S.E. Asia 7 Japan 2 Korea Rest of Asia As at 30 Sep 08 12
13 Asian Gateway Domestic 1Q FY09: 52% (4Q FY08: 52%) Asian Gateway 1Q FY09: 48% (4Q FY08: 48%) Derivatives Securities $11M 1Q FY09: 7% (4Q FY08: 6%) $71M 1Q FY09: 45% (4Q FY08: 46%) $45M 1Q FY09: 28% (4Q FY08: 25%) $31M 1Q FY09: 20% (4Q FY08: 23%) * Internal estimates 13
14 Securities Trading Activity 190 1Q FY09 4Q FY08 Change Value (S$B) SDAV (S$B) % 21.7% 170 Trading Value ($ Billion) Volume shares (in Billion shares) QFY01 3QFY01 4QFY01 1QFY02 2QFY02 3QFY02 4QFY02 1QFY03 2QFY03 3QFY03 4QFY03 1QFY04 2QFY04 3QFY04 4QFY04 1QFY05 2QFY05 3QFY05 4QFY05 1QFY06 2QFY06 3QFY06 4QFY06 1QFY07 2QFY07 3QFY07 4QFY07 1QFY08 2QFY08 3QFY08 4QFY08 1Q FY % Trading Volume (Billion Shares) Trading Value Trading Volum e 14
15 Market Access Products ETFs 2,500 2,000 1,500 1, , FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY09 Traded value of ETFs: 277% Jan to Sep 2008: S$2.2B Jan to Sep 2007: S$584M Currently, the 19 SGX listed ETFs offer exposure to: Greater China, India, Hong Kong, Japan, Korea, ASEAN, Taiwan, Gold, Commodities 15
16 Growth in Futures Volumes 1Q FY09 4Q FY08 1Q FY09 on 4Q FY08 Total contracts (in millions) % Top 4 contracts 7.2 Million Contracts QFY04 2QFY04 3QFY04 4QFY04 1QFY05 2QFY05 3QFY05 4QFY05 1QFY06 2QFY06 3QFY06 4QFY06 1QFY07 2QFY07 3QFY07 4QFY07 1QFY08 2QFY08 3QFY08 4QFY08 1QFY09 Nikkei MSCI TW MSCI SG CNX Nifty 16
17 Single Stock Derivatives Target launch: November 2008 SSDs are forward contracts traded on the SGX with a 35 day cycle. Also known as Extended Settlement (ES) contracts ES contracts on 50 stocks initially (both index and non index stocks) Margins of up to 5 to 20% of contract value Targeted at retail investors who can now long and short selected stocks listed on SGX with this product To plug the gap in the domestic derivatives revenue (7% of total revenues in 1Q FY2009) 17
18 Integrated Risk Management Practices of SGX as a Central Counterparty (CCP) Monitoring of Financial Resources & Supervision Of Clearing Members Integrated Risk Management Practices of a CCP Margins & Collateral Management Daily Monitoring Of Risk Exposures Efficient Clearing & Settlement Clearing Fund Resources 18
19 Summary Derivatives market Robust growth in derivatives market Single stock derivatives to be introduced in November 2008 Securities market SDAV above S$1 billion/ day Financials Cost management Other Key Developments SGX Prime launched on 13 October 2008 Technology refresh 19
Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012
ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationGroup 1Q FY13 financial highlights
Singapore Press Holdings 1Q FY13 Financial Results 14 January 2013 Group 1Q FY13 financial highlights 1Q FY13 S$ 000 1Q FY12 S$ 000 Change % Operating Revenue 322,092 332,406 (3.1) Operating Profit # 109,371
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016
Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationEUROZ INVESTOR CONFERENCE
Cedar Woods Properties Limited EUROZ INVESTOR CONFERENCE 14 March 2017 Cedar Woods strategy Cedar Woods Presentation 2 To grow and develop our national project portfolio, diversified by: geography product
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationAPPLIANCE TELECOMMUNICATIONS
May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017
Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Table of Contents General Information and Business Activities Economic Development of
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationCENTRALE. Monetary. compared. domestic. million.
CENTRALE BANK VAN ARUBAA Statistical News Release Second Quarter 2012 Date: November 7, 2012 Monetary and financial developments Money and credit In the second quarterr of 2012, the money supply decreased
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationSingapore Press Holdings. 1Q FY12 Financial Results 10 January 2012
Singapore Press Holdings 1Q FY12 Financial Results 10 January 2012 Group 1Q FY12 financial highlights 1Q FY12 S$ 000 1Q FY11 S$ 000 Change % Operating Revenue 332,406 318,717 4.3 Operating Profit # 121,230
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationECONOMIC EFFECTS OF SARS ON THE ASIA-PACIFIC CASE STUDY ASIAN REGION
ECONOMIC EFFECTS OF SARS ON THE ASIA-PACIFIC CASE STUDY ASIAN REGION This sample essay is provided for the purpose of study and analysis. The information contained within should be used as a guide only.
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationMay 6, 2008 First Quarter 2008 Results
SWEUB2227319CMDV7 May 6, 28 First Quarter 28 Results 1Q 28: Improved results in a challenging environment Page 2 Strong loan growth at 34.2% yoy Accelerated deposit growth at 31% yoy; improved loans /
More informationInvestor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationAsia Illicit Tobacco Indicator 2016: Hong Kong. Prepared by Oxford Economics October 2017
Asia Illicit Tobacco Indicator 6: Hong Kong Prepared by Oxford Economics October 7 Disclaimer The Asia Illicit Tobacco Indicator 6 Report (the Report ) on the illicit tobacco trade in selected Asian markets
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationFor personal use only
Cedar Woods Properties Limited EUROZ INVESTOR CONFERENCE 14 March 2017 Cedar Woods strategy Cedar Woods Presentation 2 To grow and develop our national project portfolio, diversified by: geography product
More informationCRS Report for Congress Received through the CRS Web
Order Code 95-129 ENR Updated November 3, 2003 CRS Report for Congress Received through the CRS Web Tobacco Price Support: An Overview of the Program Jasper Womach Agricultural Policy Specialist Resources,
More informationTelekom Austria Group Results for the First Quarter May 16, 2007
Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011
ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 STRUCTURE 1. National economy 2. International economy 3. Outlook 2 CENTRALE
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationBusiness Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.
Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationBancAnalysts Association of Boston Conference Presentation. November 3, 2017
BancAnalysts Association of Boston Conference Presentation November 3, 2017 Disclaimer This presentation contains forward- looking statements within the meaning of the Private Securities Litigation Reform
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationMARKET NEWS for pig meat
MARKET NEWS for pig meat Market analysis 7 May Week 19 MARKET SITUATION Europe: Trading in fresh legs is at falling prices. As regards other cuts, trading is largely at unchanged prices. Growing demand
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationEffective Tobacco Tax Reform: Evidence from China
Effective Tobacco Tax Reform: Evidence from China Rose Zheng Director, WHO Collaborating Center for Tobacco and Economics Professor, University of International Business and Economics (UIBE), Beijing,
More informationResults for the fiscal year ended March 31, 2018 Future management outlook. May 10, 2018 Takashige Negishi President and Representative Director
Results for the fiscal year ended March 31, 2018 Future management outlook May 10, 2018 Takashige Negishi President and Representative Director Offering results (Figure 1) * Percentages are relative to
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationThe Global Economic Crisis and HIV Prevention and Treatment Programmes: Vulnerabilities and Impact. Executive Summary TRINIDAD AND TOBAGO
The Global Economic Crisis and HIV Prevention and Treatment Programmes: Vulnerabilities and Impact Executive Summary TRINIDAD AND TOBAGO October 2009 ACKOWLEDGEMENT The executive summary The Global Economic
More informationResults Briefing Junichi Yoshii President & Representative Director
Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income
More informationPress release Regulated information
IBA TRADING UPDATE - THIRD QUARTER 2013 Pick up in revenues over H1 2013 due to good order book conversion Company on track to be selected for eight new proton therapy (PT) rooms in 2013 REBIT margin for
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationReport. Uganda Pharmaceutical Sector Scan JUNE 2010
Report On the Uganda Pharmaceutical Sector Scan Part of Component 1 of MeTA Baseline Assessments JUNE 2010 Drafted by consultants: 1. Samuel Balyejjusa, B.Pharm., MPH 2. Paschal Mujasi, B.Pharm., MBA 3.
More informationNASDAQ: FHCO 2016 Annual Meeting
NASDAQ: FHCO 2016 Annual Meeting Q1 2016 At a Glance NASDAQ Core product FHCO FC2 Female Condom Gross margin ~66% Operating margin ~29% Total current assets $24 million no L/T debt Profitable Starting
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationHong Leong Bank Berhad (97141 X) A Member of the Hong Leong Group. A Member of the Hong Leong Group ANNUAL REPORT 2008
Hong Leong Bank Berhad (97141 X) Hong Leong Bank Berhad (97141 X) A Member of the Hong Leong Group A Member of the Hong Leong Group ANNUAL REPORT 2008 Our Corporate Vision An Outstanding Financial Services
More information6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store
Actual Store Low Price & Great Value $5,6, 6.% CAP Rate Open & paying rent--available for immediate sale Lower price point and great value Offered free & clear; loans available today with as little as
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationFY07 Full Year Update & Overview
FY07 Full Year Update & Overview Investment Highlights Leading player in respiratory humidification systems Consistent growth strategy Estimated US$2+ billion and growing market opportunity High level
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationInvestor Presentation
Investor Presentation Spring 2019 OTCQX:MDCL www.medicinemantechnologies.com SAFE HARBOR STATEMENT: This presentation may contain forward looking statements which are based on current expectations, forecasts,
More informationReview of Half Year 2010
Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationPRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationHONG LEONG TOP YIELD ACCOUNT TERMS & CONDITIONS ( T&Cs )
Last updated on 30 May 2018 HONG LEONG TOP YIELD ACCOUNT TERMS & CONDITIONS ( T&Cs ) These terms and conditions are to be read together as a whole with the General Terms and Conditions of Accounts for
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More information